<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210415050983N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-01-09</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>A Comparison of the effect of dexmedetomidine and remifentanil on analgesia and respiratory parameters in patients undergoing stereotactic brain biopsy</public_title>
      <acronym></acronym>
      <scientific_title>A Comparison of the effect of dexmedetomidine and remifentanil on analgesia and respiratory parameters in patients undergoing stereotactic brain biopsy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-12-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/60399</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Health service research, Randomization description: En Permuted Randomized Blocks :In this method, 10 random blocks are generated by computer. Each block includes 5 people in the intervention group and 5 people in the control group. The order of these people is randomly arranged by computer and people are assigned to groups in the same way. At the end of each block, a new block of 10 is produced and this process will continue until the final sample volume is reached, Blinding description: Forms with numbers 1 and 2 are used in packaged envelopes to group patients, which are given to patients randomly and patients do not know about the envelopes. After entering the envelope operating room by the anesthesiologist in charge of the patient Opened and according to the intervention group, the drug that was prepared in advance is given to the clinical caregiver for injection. The clinical caregiver is not aware of the grouping. The evaluator and recorder of the results and the person analyzing the data are also unaware of the grouping.</study_design>
      <phase>2</phase>
      <hc_freetext>Stereotactic biopsy.</hc_freetext>
      <i_freetext>Intervention 1: First, under local anesthesia of the scalp with 20 cc of 1.5% lidocaine and 50 micrograms of intravenous fentanyl, a stereotactic form is installed for the patient and the patient is transferred to radiology for MRI. Then 2 liters of oxygen per minute with a mask, 5 cc of normal saline per hour and 0.003 mg per kg of intravenous midazolam are given. Group D receive intravenous dexmedetomidine at the rate of 0.5 micrograms per kg per 10 minutes for 10 minutes. Then 0.5 micrograms per kilogram per hour is given by the infusion pump during the procedure. Intervention 2: First, under local anesthesia of the scalp with 20 cc of 1.5% lidocaine and 50 micrograms of intravenous fentanyl, a stereotactic form is installed for the patient and the patient is transferred to radiology for MRI. Then 2 liters of oxygen per minute with a mask, 5 cc of normal saline per hour and 0.003 mg per kg of intravenous midazolam are administered. Group R Remifentanil 1 microgram per kilogram of bolus and then 0.05 to 0.2 micrograms per kilogram. Receives grams per minute by infusion pump.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
En All data(questionnaire and the Excel file) can be shared after identifying individuals.

When:
Start access 6 months after printing results

To whom:
En Researchers working in academic institutions

Conditions:
En If the study is conducted in a larger area between several hospitals

Where to obtain:
En Email: drasgari98429@gmail.com Phone : 09127421711 Mrs. Dr. Sogol Asgari

How to obtain:
En After identifying the people, the questionnaire and the Excel file will be sent via e-mail within a week.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sogol Asgari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>South Kargar St. Kamali St. Special Loghman Hakim Hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1333635445</zip>
        <telephone>+98 21 5541 9005</telephone>
        <email>drasgari98429@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Faranak Behnaz</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Valiasr St. Tajrish Square (Quds)</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1989934148</zip>
        <telephone>+98 21 25719</telephone>
        <email>Faranak.behnaz@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients 18-50 years old candidate for stereotactic
Patients with supratentorial lesions with or without hydrocephalus
No dysfunction of the liver and kidneys
No drug addiction
Consent to participate in the study</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>50 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>BMI &gt;35 or&lt;16
mental disorder
Uncontrolled epilepsy
Alcohol and drug abuse
Having a comorbid condition such as high blood pressure
History of chronic pain
Patients with brainstem lesions
Intubated patients</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>N/A</i_code>
      <i_code>N/A</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First, under local anesthesia of the scalp with 20 cc of 1.5% lidocaine and 50 micrograms of intravenous fentanyl, a stereotactic form is installed for the patient and the patient is transferred to radiology for MRI. Then 2 liters of oxygen per minute with a mask, 5 cc of normal saline per hour and 0.003 mg per kg of intravenous midazolam are given. Group D receive intravenous dexmedetomidine at the rate of 0.5 micrograms per kg per 10 minutes for 10 minutes. Then 0.5 micrograms per kilogram per hour is given by the infusion pump during the procedure.</i_keyword>
      <i_keyword>First, under local anesthesia of the scalp with 20 cc of 1.5% lidocaine and 50 micrograms of intravenous fentanyl, a stereotactic form is installed for the patient and the patient is transferred to radiology for MRI. Then 2 liters of oxygen per minute with a mask, 5 cc of normal saline per hour and 0.003 mg per kg of intravenous midazolam are administered. Group R Remifentanil 1 microgram per kilogram of bolus and then 0.05 to 0.2 micrograms per kilogram. Receives grams per minute by infusion pump.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Hemodynamic parameters. Timepoint: Every 5 minutes from the moment you enter the operating room. Method of measurement: monitoring.</prim_outcome>
      <prim_outcome>Respiratory parameters. Timepoint: Every 5 minutes from the moment you enter the operating room. Method of measurement: monitoring.</prim_outcome>
      <prim_outcome>Seadation. Timepoint: Every 5 minutes from the moment you enter the operating room. Method of measurement: Ramssy Criteria.</prim_outcome>
      <prim_outcome>Analgesia. Timepoint: Every 5 minutes from the moment you enter the operating room. Method of measurement: VAS criteria.</prim_outcome>
      <prim_outcome>Recovery from sedation. Timepoint: Every 10 minutes after the procedure. Method of measurement: Aldert criteria.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-12-01</approval_date>
        <contact_name>Vice for Research and Technology, Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>Velenjak, Yemen Street, Shahid Shahriari Square Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
